Clinical trials · Boston, MA
Breast cancer clinical trials in Boston
We’re tracking 158 recruiting breast cancer studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT06016738RecruitingPhase 3
Palazestrant vs standard therapy for advanced breast cancer
This trial compares a new oral drug, palazestrant (OP-1250), to standard hormone therapies for people with ER+/HER2- advanced breast cancer that has worsened after prior hormone therapy. It tests whether palazestrant can better control the cancer.
Boston, MassachusettsAges 18 years+ - NCT06638307RecruitingPhase 1
Study of new drug MEN2312 for advanced breast cancer with specific genetic changes
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
Boston, MassachusettsAges 18 years+ - NCT05142800Recruiting
Screening for Lymphedema in Breast Cancer Targeted Therapy
This study is looking at whether targeted therapy for breast cancer changes the risk of arm swelling (lymphedema). It is a screening trial that uses a machine to measure arm size and check for any swelling early on.
Boston, MassachusettsAges 18–80 - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Boston, MassachusettsAges 18 years+ - NCT05307705RecruitingPhase 1
Testing LOXO-783 for PIK3CA-mutated cancers
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Boston, MassachusettsAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
Boston, MassachusettsAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Boston, MassachusettsAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Boston, MassachusettsAges 18 years+ - NCT07553572Recruiting
Smartphone app to track cancer symptoms during treatment
This study tests a smartphone application designed to help you monitor and manage side effects and symptoms while you're receiving chemotherapy or other systemic treatment for breast cancer, colorectal cancer, or lymphoma. The app may help your doctors catch problems early and support you throughout your treatment.
Boston, MassachusettsAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Boston, MassachusettsAges 18–60 - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Boston, MassachusettsAges 18 years+ - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Boston, MassachusettsAges 18 years+ - NCT04230109RecruitingTeam says not enrollingPhase 2
Sacituzumab Govitecan for newly diagnosed TNBC
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
Boston, MassachusettsAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Boston, MassachusettsAges 18 years+ - NCT07592793Enrolling by invitation
Community Health Worker Perspectives on New Programs
This study asks community health center workers and partner staff about their experiences implementing a new health program. Your feedback helps researchers understand what works and what challenges exist in delivering care in community settings.
Boston, MassachusettsAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Boston, MassachusettsAges 18 years+ - NCT07597837Recruiting
Breast Cancer Surgery Outcomes Study
This study collects information about breast cancer surgery outcomes—with or without reconstruction—to help doctors understand what works best for patients. By participating, you'll contribute to research that may improve care for future patients.
Boston, MassachusettsAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Boston, MassachusettsAges 18 years+ - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Boston, MassachusettsAges 18 years+ - NCT06275126Recruiting
Choosing the Best Surgery for Young Women with Breast Cancer
This study looks at how to make the best surgical choices for young women with breast cancer. It compares different surgery options to help guide treatment decisions.
Boston, MassachusettsAges 18–44 - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Boston, MassachusettsAges 18 years+ - NCT04986579RecruitingPhase 2
Scalp cooling to reduce hair loss during breast cancer chemotherapy
This Phase 2 trial tests whether using a scalp-cooling device during chemotherapy can help prevent or lessen hair loss in people with metastatic invasive breast cancer. You would need to be starting a specific chemotherapy plan and be willing to begin scalp cooling with your first treatment.
Boston, MassachusettsAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Boston, MassachusettsAges 18 years+
Hear when a new Breast cancer trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Breast cancer trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting breast cancer studies listed above.
- Dana-Farber Cancer Institute · 14 studies
- Massachusetts General Hospital · 14 studies
- Beth Israel Deaconess Medical Center · 5 studies
- Tufts Medical Center · 3 studies
- Brigham and Women's Hospital · 2 studies
- Dana-Farber Cancer Institute - Merrimack Valley · 2 studies
- Dana-Farber Cancer Institute at Foxborough · 2 studies
- Dana-Farber/Brigham and Women's Cancer Center at South Shore · 2 studies
What taking part in a breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting breast cancer studies in Massachusetts.
Common questions
- Are there breast cancer clinical trials near Boston?
- Yes. We're currently tracking 158 recruiting breast cancer studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast cancer study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast cancer studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.